CBUS
Price
$1.23
Change
-$0.12 (-8.89%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
64.62M
Intraday BUY SELL Signals
RGNX
Price
$11.64
Change
+$0.04 (+0.34%)
Updated
Nov 13 closing price
Capitalization
589.25M
109 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CBUS vs RGNX

Header iconCBUS vs RGNX Comparison
Open Charts CBUS vs RGNXBanner chart's image
Cibus
Price$1.23
Change-$0.12 (-8.89%)
Volume$921
Capitalization64.62M
REGENXBIO
Price$11.64
Change+$0.04 (+0.34%)
Volume$561.03K
Capitalization589.25M
CBUS vs RGNX Comparison Chart in %
CBUS
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CBUS vs. RGNX commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CBUS is a Hold and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (CBUS: $1.35 vs. RGNX: $11.60)
Brand notoriety: CBUS and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CBUS: 18% vs. RGNX: 92%
Market capitalization -- CBUS: $64.62M vs. RGNX: $589.25M
CBUS [@Biotechnology] is valued at $64.62M. RGNX’s [@Biotechnology] market capitalization is $589.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CBUS’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • CBUS’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than CBUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CBUS’s TA Score shows that 3 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • CBUS’s TA Score: 3 bullish, 7 bearish.
  • RGNX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than CBUS.

Price Growth

CBUS (@Biotechnology) experienced а +2.66% price change this week, while RGNX (@Biotechnology) price change was -0.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

RGNX is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($589M) has a higher market cap than CBUS($64.6M). RGNX YTD gains are higher at: 50.065 vs. CBUS (-51.439). RGNX has higher annual earnings (EBITDA): -129.93M vs. CBUS (-262.49M). RGNX has more cash in the bank: 323M vs. CBUS (36.5M). CBUS has less debt than RGNX: CBUS (35.4M) vs RGNX (77.7M). RGNX has higher revenues than CBUS: RGNX (156M) vs CBUS (4.85M).
CBUSRGNXCBUS / RGNX
Capitalization64.6M589M11%
EBITDA-262.49M-129.93M202%
Gain YTD-51.43950.065-103%
P/E RatioN/AN/A-
Revenue4.85M156M3%
Total Cash36.5M323M11%
Total Debt35.4M77.7M46%
FUNDAMENTALS RATINGS
CBUS vs RGNX: Fundamental Ratings
CBUS
RGNX
OUTLOOK RATING
1..100
8870
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
8743
P/E GROWTH RATING
1..100
10017
SEASONALITY SCORE
1..100
42n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CBUS's Valuation (14) in the null industry is somewhat better than the same rating for RGNX (72) in the Biotechnology industry. This means that CBUS’s stock grew somewhat faster than RGNX’s over the last 12 months.

CBUS's Profit vs Risk Rating (100) in the null industry is in the same range as RGNX (100) in the Biotechnology industry. This means that CBUS’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (97) in the Biotechnology industry is in the same range as CBUS (99) in the null industry. This means that RGNX’s stock grew similarly to CBUS’s over the last 12 months.

RGNX's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for CBUS (87) in the null industry. This means that RGNX’s stock grew somewhat faster than CBUS’s over the last 12 months.

RGNX's P/E Growth Rating (17) in the Biotechnology industry is significantly better than the same rating for CBUS (100) in the null industry. This means that RGNX’s stock grew significantly faster than CBUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CBUSRGNX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 7 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
CBUS
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OCMAX32.121.02
+3.28%
OCM Gold Atlas
ARIFX13.340.07
+0.53%
Aristotle International Eq I
HCAYX60.980.02
+0.03%
Hartford Capital Appreciation Y
GSCLX34.15-0.06
-0.18%
Goldman Sachs Large Cap Gr Insghts Svc
CUSRX13.10-0.08
-0.61%
Cullen Small Cap Value Retail

CBUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CBUS has been loosely correlated with RXRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CBUS jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CBUS
1D Price
Change %
CBUS100%
+2.27%
RXRX - CBUS
41%
Loosely correlated
-1.27%
HOWL - CBUS
38%
Loosely correlated
-3.54%
RGNX - CBUS
37%
Loosely correlated
+0.43%
ABSI - CBUS
34%
Loosely correlated
-1.45%
ABOS - CBUS
34%
Loosely correlated
-1.02%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+0.43%
SYRE - RGNX
56%
Loosely correlated
+0.34%
DNLI - RGNX
55%
Loosely correlated
-0.34%
BEAM - RGNX
54%
Loosely correlated
-2.71%
VYGR - RGNX
54%
Loosely correlated
-0.23%
MGNX - RGNX
53%
Loosely correlated
-3.29%
More